🔗 Share this article

An underground market for unapproved slimming medications is propelled by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Investigational Treatment Gaining Popularity Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its alleged fat-burning properties. Followers are encouraged to message these accounts directly for source information, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Additionally, a robust market exists on messaging services, where communities with thousands of members share comparison images, injection guides and claims of rapid UK delivery. Vendors market the substance there before redirecting customers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Early trials indicate it could assist individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Voice Concerns

However, doctors and chemists have cautions that the sale of what remains an unlicensed medication in the UK is worrisome and could result in individuals administering products of uncertain source.

Some experts said the popularity for retatrutide could be connected to the rising price of licensed weight loss products such as Mounjaro.

Legal Status and Enforcement

Selling the unapproved drug on social media or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the British medical regulations.

Some content creators try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach pharmaceutical, advertising, and consumer regulations, risking penalties, legal action or imprisonment.

Service Response and Material Removal

According to the social media company, the service has removed problematic content and banned associated keywords and query recommendations. The organization stated it was committed to keeping the platform secure and investing in enhancing compliance measures.

Online Trading Operations

Research also found communities with up to 9,000 members selling retatrutide using the platform's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” instantly brings up groups with numerous of users, filled with images of slimming results, glowing testimonials and detailed guides for mixing or injecting at residence.

Within moments of entering one group, a vendor shared contact information, where the majority of transactions take place. The vendor provided an guidebook and guaranteed shipping within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None inquired about weight, medical conditions or past usage.

Item Information and Pricing

Within these groups, messages display black plastic parcels with postal service stickers, stating to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at home with sterile water, or pre-filled injectors usually priced at £160 for 20mg. When questioned how long a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A representative for Telegram said it regularly moderated dangerous content on its platform including content that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are injecting substances they cannot confirm. Although the science behind this drug is sound, these digital products may not include what they advertise,” stated Jason Murphy, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the increase in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to social media. But fake treatments are extremely risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she said.

Her team has previously encountered individuals injured by self-injection from unconfirmed sources. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your well-being,” stated the doctor. “These substances could be impure or improperly measured.”

Producer Position

A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they said, noting that any item “falsely representing itself as a company experimental substance not yet approved … may subject patients to potentially significant medical dangers”.